Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Lexaria Bioscience ( (LEXX) ) is now available.
Lexaria Bioscience Corp. has received approval to begin its first-ever human study of DehydraTECH-liraglutide, an oral version of the GLP-1 weight loss and diabetes drug liraglutide. The study, involving 8-10 healthy volunteers, will compare the oral formulation with the conventional injected version, potentially advancing Lexaria’s technology as a leading drug delivery method. Successful outcomes could lead to further clinical trials, potentially impacting the market for GLP-1 drugs significantly and providing new options for patients and healthcare providers.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on optimizing the oral delivery of pharmaceutical compounds. The company is known for its DehydraTECH technology, which aims to enhance the effectiveness and efficiency of orally administered drugs, particularly in the weight loss and diabetes sector.
YTD Price Performance: -16.09%
Average Trading Volume: 190,868
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $33.88M
Find detailed analytics on LEXX stock on TipRanks’ Stock Analysis page.
